Amrita Krishnan

Dr. Amrita Krishnan serves as Professor in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope, holding the Nason-Hollingsworth Endowed Chair for Multiple Myeloma. She is Executive Medical Director of Hematology at City of Hope Orange County and Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research. Dr. Krishnan is a key member of multiple clinical teams including Bone Marrow and Stem Cell Transplantation, Myeloma, and Hematology & Hematopoietic Cell Transplantation.

Dr. Krishnan's educational background includes:

• M.D. from Albany Medical College (1990)
• B.S. in Biology/Modern Languages from Union College (1988)
• Residency at Strong Memorial Hospital, University of Rochester (1991-1993)
• Fellowships at City of Hope, Beth Israel Hospital/Harvard, Dana Farber Cancer Institute, and Fred Hutchinson Cancer Research Center

Dr. Krishnan is a leading researcher in multiple myeloma with specific focus on developing new drugs for relapsed myeloma and understanding mechanisms of disease resistance. Her groundbreaking work includes bringing successful transplant therapy to HIV patients with lymphoma, demonstrating remarkable patient outcomes where others had given up hope. She has served on the steering committee of the Multiple Myeloma Research Foundation, as North American representative to the International Myeloma Society, former chair of the Blood and Marrow Transplant Clinical Trials Network myeloma committee, and Co-Chair of major myeloma transplant trials in the U.S.

Analysis of Dr. Krishnan's recent publications reveals a strong focus on novel immunotherapies for multiple myeloma, particularly BCMA-targeted therapies like teclistamab and GPRC5D-targeted therapies like talquetamab. Her research spans understanding mechanisms of resistance to these therapies, optimizing pharmacokinetics, evaluating long-term outcomes, and investigating the tumor microenvironment. She also conducts significant work on hematopoietic cell transplantation outcomes, quality of life metrics, and the intersection of cardiovascular health with myeloma treatment.

Dr. Krishnan's primary scientific honor is the Nason-Hollingsworth Endowed Chair for Multiple Myeloma at City of Hope, recognizing her leadership and contributions to the field.

As Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research, Dr. Krishnan leads a comprehensive research program focused on advancing multiple myeloma treatment. Her clinical trials work has significantly impacted treatment paradigms, particularly in relapsed/refractory disease. She has been instrumental in numerous landmark clinical trials that have shaped current standards of care for multiple myeloma patients.

Dr. Krishnan directs the Judy and Bernard Briskin Center for Multiple Myeloma Research at City of Hope, which focuses on developing novel therapies and understanding disease mechanisms in multiple myeloma. Her center works closely with clinical teams to translate research findings into patient care, with particular emphasis on immunotherapies and overcoming treatment resistance.